[Federal Register: March 8, 2006 (Volume 71, Number 45)]
[Notices]
[Page 11671]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr08mr06-98]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Government-Owned Inventions; Availability for Licensing and
Cooperative Research and Development Agreements (CRADAs)
AGENCY: Centers for Disease Control and Prevention Technology Transfer
Office; Department of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention named in this notice is owned by agencies of the
United States Government and is available for licensing in the United
States (U.S.) in accordance with 35 U.S.C. 207, and is available for
cooperative research and development agreements (CRADAs) in accordance
with 15 U.S.C. 3710a, to achieve expeditious commercialization of
results of federally funded research and development. A provisional
patent application has been filed. A Patent Cooperation Treaty (PCT)
application and national stage foreign patent applications claiming
priority to the Patent Cooperation Treaty (PCT) application are
expected to be filed within the appropriate deadlines to extend market
coverage for U.S. companies and may also be available for licensing.
ADDRESSES: Licensing and CRADA information, and information related to
the technology listed below, may be obtained by writing to Suzanne
Seavello Shope, J.D., Technology Licensing and Marketing Scientist,
Technology Transfer Office, Centers for Disease Control and Prevention
(CDC), Mailstop K-79, 4770 Buford Highway, Atlanta, GA 30341, telephone
(770)488-8613; facsimile (770)488-8615; or e-mail sshope@cdc.gov. A
signed Confidential Disclosure Agreement (available under Forms at
http://www.cdc.gov/tto) will be required to receive copies of
unpublished patent applications and other information.
Diagnostics
Immunoassay for Diagnosis of Orthopoxvirus Infection
A CDC-developed immunoassay may be used for the diagnosis of
infection with Orthopoxviruses (e.g. Monkeypox, Variola) by detection
of acute phase immune responses that correlate to recent infection.
With recent recognition of Orthopox viruses as emerging infectious
agents with zoonotic transmission capabilities as well as select agents
for bioterrorism, assays for the detection or diagnosis of infections
are sought. This assay provides a rapid and simple method for detection
of infection with these viruses related to zoonotic transmission or
bioterrorism events involving such viruses.
Use of the assay produced high levels of sensitivity during the
2003 Monkeypox outbreak in North America when compared to PCR.
Commercialization of the ELISA test may provide a standard screening
tool for diagnosis of Orthopoxvirus as well as a surveillance tool for
exposure.
The immunoassay may also be useful at the state level for BT
surveillance including an opportunity for use in reference labs.
Reagents used in the assay are available through CDC laboratories and
for commercial development of the assay. Further refinement of the
assay may result in the development of additional reagents for
incorporation into the assay.
Inventors: Kevin L. Karem, Inger K. Damon and Joanne L. Patton.
CDC Ref. #: I-014-04.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E6-3267 Filed 3-7-06; 8:45 am]
BILLING CODE 4163-18-P